{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T14:26:25Z","timestamp":1744986385772},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.56.7908","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T22:09:49Z","timestamp":1498860589000},"page":"1679-1686","source":"Crossref","is-referenced-by-count":6,"title":["Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience"],"prefix":"10.2169","volume":"56","author":[{"given":"Takayuki","family":"Katsuno","sequence":"first","affiliation":[{"name":"Department of Nephrology, Internal Medicine Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takenori","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Internal Medicine Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hangsoo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Internal Medicine Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritoshi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Internal Medicine Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Internal Medicine Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Internal Medicine Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Ishimoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Internal Medicine Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Kosugi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Internal Medicine Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotake","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Internal Medicine Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Internal Medicine Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Internal Medicine Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Beck LH Jr, Salant DJ. Membranous nephropathy: recent travels and new roads ahead. Kidney Int 77: 765-770, 2010."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009.","DOI":"10.1056\/NEJMoa0810457"},{"key":"3","unstructured":"3. du Buf-Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am J Kidney Dis 46: 1012-1029, 2005."},{"key":"4","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","volume":"360","author":"G Remuzzi","year":"2002","unstructured":"4. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 360: 923-924, 2002.","journal-title":"The Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"5","unstructured":"5. Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 14: 1851-1857, 2003."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73: 117-125, 2008.","DOI":"10.1038\/sj.ki.5002628"},{"key":"7","unstructured":"7. Fervenza FC, Abraham RS, Erickson SB, et al.; Mayo Nephrology Collaborative Group. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 5: 2188-2198, 2010."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 23: 1416-1425, 2012.","DOI":"10.1681\/ASN.2012020181"},{"key":"9","unstructured":"9. Cravedi P, Sghirlanzoni MC, Maras\u00e0 M, Salerno A, Remuzzi G, Ruggenenti P. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am J Nephrol 33: 461-468, 2011."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2: 932-937, 2007.","DOI":"10.2215\/CJN.01180307"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nishi S, Ubara Y, Utsunomiya Y, et al. Evidence-based clinical practice guidelines for nephrotic syndrome 2014. Clin Exp Nephrol 20: 342-370, 2016.","DOI":"10.1007\/s10157-015-1216-x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Beck LH Jr, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22: 1543-1550, 2011.","DOI":"10.1681\/ASN.2010111125"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol 26: 2545-2558, 2015.","DOI":"10.1681\/ASN.2014070640"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Prunotto M, Carnevali ML, Candiano G, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 21: 507-519, 2010.","DOI":"10.1681\/ASN.2008121259"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ruggenenti P, Chiurchiu C, Abbate M, et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 1: 738-748, 2006.","DOI":"10.2215\/CJN.01080905"},{"key":"16","unstructured":"16. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH. Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 4: 734-744, 2009."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Shiiki H, Saito T, Nishitani Y, et al.; Research Group on Progressive Renal Diseases in Japan. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int 65: 1400-1407, 2004.","DOI":"10.1111\/j.1523-1755.2004.00518.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Fervenza FC, Canetta PA, Barbour SJ, et al.; Mentor Consortium group. A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR). Nephron 3: 159-168, 2015.","DOI":"10.1159\/000430849"},{"key":"19","unstructured":"19. Rojas-Rivera J, Fern\u00e1ndez-Ju\u00e1rez G, Ortiz A, et al. A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study. Clin Kidney J 5: 503-510, 2015."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/13\/56_56.7908\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T02:37:50Z","timestamp":1569638270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/13\/56_56.7908\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":19,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.56.7908","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}